BridgeMD
New treatment option for Atrial Fibrillation
Official title Zenith LAA Occlusion System
ClinicalTrials.gov ID: NCT05951101
What this study is testing
- What it's testing
- Demonstrate the safety and performance of the Zenith LAA Occlusion System and procedure to occlude the Left Atrial Appendage (LAA) from the left atrium (LA) using a minimally invasive technique. Indication - LAA closure in patients with non-valvular atrial fibrillation, with an ostial diameter between 18 mm and 26 mm
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 at the time of screening
- Documented diagnosis of non-valvular AF
- Clinical indication for LAA occlusion
- Willing and able to return to and comply with scheduled follow-up visits and testing, including medical treatment as required by the protocol.
- Willing and able to provide written informed consent
You likely can't join if
- Within 30 days before the procedure date:
- Exhibited NYHA class III or IV heart failure symptoms
- Known bleeding disorders (such as bleeding diathesis, thrombocytopenia [platelet count \ 2 [spontaneous]) Within 90 days before the procedure date:
- Documented history of myocardial infarction or unstable angina
- Documented embolic stroke, TIA or suspected neurologic event
- Chronic renal insufficiency (eGFR ≤15mL/min per 1.73 m2 (CKD-EPI)) or end-stage renal disease
See the full eligibility criteria
Who can join
- Age ≥18 at the time of screening
- Documented diagnosis of non-valvular AF
- Clinical indication for LAA occlusion
- Willing and able to return to and comply with scheduled follow-up visits and testing, including medical treatment as required by the protocol.
- Willing and able to provide written informed consent
What rules you out
- Within 30 days before the procedure date:
- Exhibited NYHA class III or IV heart failure symptoms
- Known bleeding disorders (such as bleeding diathesis, thrombocytopenia [platelet count \ 2 [spontaneous]) Within 90 days before the procedure date:
- Documented history of myocardial infarction or unstable angina
- Documented embolic stroke, TIA or suspected neurologic event
- Chronic renal insufficiency (eGFR ≤15mL/min per 1.73 m2 (CKD-EPI)) or end-stage renal disease
- Requires long-term oral anticoagulation therapy for a condition other than AF
- Diagnosed active local or systemic infection, septicaemia, active pericarditis, or fever of unknown origin
- Known acquired or inherited propensity for forming blood clots (e.g., malignancy and factor V Leiden mutation) established by prior objective testing
- Contraindication to the standard of care post-implantation antithrombotic medication regime (e.g., dual antiplatelet therapy (DAPT)/direct oral anticoagulant (DOAC)
- Rheumatic heart disease
- Implanted mechanical valve prosthesis
- Documented carotid disease, defined as greater than 70% stenosis without symptoms or greater than 50% stenosis with symptoms
- Body mass index greater than 40 kg/m2
- Patient is pregnant or breastfeeding or plans/desires to get pregnant within the next 12 months post-procedure
- Current or planned enrolment in an investigation or study of an investigational device or investigational drug that would interfere with this study and the required follow-up
- Mental impairment or other psychiatric conditions which may not allow the patient to understand the nature, significance, and scope of the study
- Any other criteria (including physical and mental health), medical illness, or comorbidity which would make the subject unsuitable to participate in this study as determined by the clinical site principal investigator
- Patients with known allergy or sensitivity to nitinol (nickel and titanium) or any of the other materials in the Zenith LAA Occlusion System Implant
- Life expectancy of less than 1 year
- Inability, unwillingness, or contraindication to undergo Trans-Oesophageal and/or Trans-Thoracic Echocardiogram (TOE/TTE) or Cardiac Computed Tomography Angiography (CCTA) imaging or any catheterisation procedures
- Any anatomical condition that precludes the patient from undergoing LAA occlusion with the AuriGen Zenith LAA Occlusion System implant procedure, as determined by the principal investigator Imaging Exclusion Criteria:
- Patients with a maximal ostial left atrial appendage diameter \>25 mm or \<17 mm by pre-procedural ECG-gated CT scan, to fit the Zenith LAA Occlusion System
- Patients where CCTA analysis suggests that the Zenith LAA Occlusion System may not be suitable
- Intracardiac thrombus diagnosed by CCTA or echocardiography
- Previous occlusion/ligation of the LAA (by any surgical or percutaneous method)
- Documented presence of implanted closure devices (e.g. Atrial septal defect (ASD), Patent foramen ovale (PFO) or Ventricular septal defect (VSD) device) for congenital defect treatment
- Documented Left Ventricular Ejection Fraction (LVEF) \<30%
The study team makes the final eligibility decision.
Where it's taking place
- Parkville, Victoria, Australia
- Auckland, New Zealand
- Christchurch, New Zealand
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Parkville, Victoria, Australia; Auckland, New Zealand; Christchurch, New Zealand. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.